Home › Compare › SDCVF vs ABBV
SDCVF yields 2.82% · ABBV yields 3.06%● Live data
📍 SDCVF pulled ahead of the other in Year 6
Combined, SDCVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SDCVF + ABBV for your $10,000?
Vicat S.A. produces and sells cement, ready-mixed concrete, and aggregates. The company operates in three segments: Cement, Concrete & Aggregates, and Other Products & Services. It offers various cement products, including Portland cement, Portland composite cement, blast furnace cement, slag cement, and Pozzolan cement for the general contractors, such as concrete mixers; manufacturers of precast concrete products; construction and public works contractors; local authorities; residential property developers or master masons; and construction material wholesalers or retail chains. The company also provides ready-mixed concrete comprising standard and special concrete for the construction and public works contractors, including construction groups, house building companies, farmers, or private individuals, as well as industrial, commercial buildings, roads, bridges, tunnels, and highways; aggregates, such as sands and gravel products for the ready-mixed concrete and precast concrete products manufacturers. In addition, it offers construction chemicals for use in exterior wall coatings, mortar and traditional concretes, tiling adhesives, and thermal insulation products, as well as for the products used to repair floors and walls; adhesives, and paper bags for the agro-food, chemical, and construction sectors. Further, the company provides various services comprising logistics, transportation, and distribution. It operates in France, Switzerland, Italy, the United States, Turkey, Egypt, Senegal, Mali, Mauritania, Kazakhstan, India, and Brazil. Vicat S.A. was incorporated in 1853 and is headquartered in L'Isle-d'Abeau, France.
Full SDCVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.